OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07153705

Enrollment

Registered

2025-09-04

Start date

2025-09-01

Completion date

2026-04-01

Last updated

2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Brief summary

To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Women over 18 years old; 2. Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor; 3. ECOG \< 2; 4. The expected survival period exceeds 6 months; 5. CA125 ≤ 35 U/ml before initial treatment; 6. Undergo surgery and adjuvant chemotherapy; 7. The period between diagnosis and enrollment does not exceed 8 weeks; 8. Be willing to provide blood samples for OCS testing during the research process; 9. Sign the informed consent form.

Exclusion criteria

1. Have had other malignant tumors within the last five years; 2. Have received any treatment for ovarian cancer; 3. Benign ovarian mass; 4. Non-primary ovarian tumors; 5. Combined with other malignant tumors; 6. Patients receiving neoadjuvant therapy; 7. Pregnancy.

Design outcomes

Primary

Measure	Time frame
OCS product inspection	Before the operation

Outcome results